Company Description
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia.
It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines.
It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs.
TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Harlan F. Weisman |
Contact Details
Address: 2600 Via Fortuna, Suite 360 Austin, Texas 78746 United States | |
| Phone | 737-802-1973 |
| Website | tffpharma.com |
Stock Details
| Ticker Symbol | TFFP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001733413 |
| CUSIP Number | 87241J104 |
| ISIN Number | US87241J2033 |
| Employer ID | 82-4344737 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harlan F. Weisman | President, Chief Executive Officer and Director |
| Kirk Allen Coleman | Chief Financial Officer, Treasurer and Secretary |
| Dr. Zamaneh Mikhak M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 8-K | Current Report |
| Jun 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 7, 2024 | 8-K | Current Report |
| May 17, 2024 | 424B5 | Filing |
| May 17, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 2, 2024 | 8-K | Current Report |